更新于：2024-12-26
Eftilagimod alpha
重组人源淋巴细胞激活基因-3（hLAG-3）融合蛋白(Immutep)
更新于：2024-12-26
概要
基本信息
药物类型 融合蛋白 |
别名 Efti、Eftilagimod Alfa、eftilagimod alfa + [14] |
作用机制 HLA class II抗原调节剂、LAG3抑制剂(淋巴细胞活化基因3蛋白抑制剂)、Antigen-presenting cells 刺激剂(抗原呈递细胞 刺激剂) |
在研适应症 |
原研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评快速通道 (美国) |
登录后查看时间轴
序列信息
Sequence Code 17007211
来源: *****
关联
23
项与 重组人源淋巴细胞激活基因-3（hLAG-3）融合蛋白(Immutep) 相关的临床试验TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination with Pembrolizumab (PD-1 Antagonist) and Chemotherapy.
The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) among adults with metastatic non-small cell lung cancer (NSCLC).
Participants will receive either efti plus standard treatment (pembrolizumab and platinum doublet chemotherapy) or placebo plus standard treatment and will be treated for up to 2 years.
Participants will receive either efti plus standard treatment (pembrolizumab and platinum doublet chemotherapy) or placebo plus standard treatment and will be treated for up to 2 years.
开始日期2025-03-01 |
申办/合作机构 Immutep SAS [+1] |
Phase II, Single-arm Clinical Trial Evaluating Efficacy and Safety of Pembrolizumab in Combination with a Soluble LAG-3 Protein, Eftilagimod Alpha, and Radiotherapy in Neoadjuvant Treatment of Patients with Soft Tissue Sarcomas (EFTISARC-NEO)
This is a phase II single-arm single-stage study evaluating efficacy and safety of pembrolizumab in combination with a soluble LAG-3 protein, eftilagimod alpha (Efti) and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas. This study will determine the pathologic response rate (defined as percentage of tumor hyalinization/fibrosis) to the combination treatment.
开始日期2023-07-17 |
AIPAC-002 (Active Immunotherapy PAClitaxel-002): A Multicentre, Phase Ib Study to Test a New Schedule of Eftilagimod Alpha (a Soluble LAG-3 Protein) as Adjunctive to Weekly Paclitaxel in Hormone Receptor-positive Metastatic Breast Carcinoma Patients
This is a multicentre, multinational Phase Ib study in female HR+ MBC patients not receiving Her2-targeted therapy. Treatment consists of a chemo-immunotherapy phase followed by a maintenance phase. The chemo-immunotherapy phase consists of 6 cycles of 4 weeks each. During each cycle the subject will receive 80 mg/m2 paclitaxel intravenously on Day 1, 8 and 15 and 30 mg efti subcutaneously on Day 1 and 15 in a 28-day (4-week) cycle. Efti will always be given after paclitaxel. The maintenance phase comprises 6 visits with 4 weekly intervals; during each such visit 30 mg efti is given subcutaneously as monotherapy. A total of 24 subjects will be enrolled into the study. The primary goal of the study is safety and tolerability profile of efti in combination with weekly paclitaxel both given the same day in contrast to subsequent days as in the AIPAC trial.
开始日期2023-06-01 |
申办/合作机构 |
100 项与 重组人源淋巴细胞激活基因-3（hLAG-3）融合蛋白(Immutep) 相关的临床结果
登录后查看更多信息
100 项与 重组人源淋巴细胞激活基因-3（hLAG-3）融合蛋白(Immutep) 相关的转化医学
登录后查看更多信息
100 项与 重组人源淋巴细胞激活基因-3（hLAG-3）融合蛋白(Immutep) 相关的专利（医药）
登录后查看更多信息
31
项与 重组人源淋巴细胞激活基因-3（hLAG-3）融合蛋白(Immutep) 相关的文献（医药）2024-11-01·JTO clinical and research reports
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
Article
作者: Roxburgh, Patricia ; Krebs, Matthew G. ; Majem, Margarita ; Clay, Tim ; Mueller, Christian ; Andres, B. ; Doger, Bernard ; Triebel, F. ; Krebs, Matthew G ; Doger, B. ; Forster, Martin ; Majem, M. ; Triebel, Frédéric ; Forster, M. ; Iams, W. ; Clay, T. ; Bajaj, P. ; Iams, Wade ; Perera, Suvini ; Peguero, J. ; Mueller, C. ; Bajaj, Pawan ; Barba, Andres ; Krebs, M.G. ; Roxburgh, P. ; Perera, S. ; Peguero, Julio
Introduction:
Eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, triggers antigen-presenting cell and T-cell (CD4+ and CD8+) activation and helps overcome resistance to programmed cell death protein 1 or programmed cell death-ligand 1 (PD-(L)1) inhibitors. We assessed efti plus pembrolizumab in second-line anti-PD-(L)1-refractory metastatic patients with NSCLC.
Methods:
After confirmed progression on anti-PD-(L)1-based first-line therapy, patients received efti (30 mg subcutaneously every 2 weeks for eight 3-week cycles and then every 3 weeks for up to 54 weeks) plus pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks). The primary endpoint was the objective response rate by modified Response Evaluation Criteria in Solid Tumors version 1.1 for immune-based therapies. Secondary endpoints included disease control rate, progression-free survival, overall survival (OS), and tolerability. Exploratory endpoints included tumor growth kinetics and predefined subgroup analyses. Programmed cell death-ligand 1 tumor proportion score was assessed centrally.
Results:
Thirty-six patients were enrolled from April 2019 to August 2021 using Simon's two-stage design. Most patients (81.8%) had low or negative (<50%) PD-(L)1 tumor proportion score. First-line therapy was anti-PD-(L)1-based for all patients, combined with chemotherapy for 66.7%. The confirmed objective response and disease control rates were 8.3% and 33.3%. The median progression-free survival was 2.1 months and the median OS was 9.9 months. Patients exhibiting high PD-(L)1 expression or acquired resistance to PD-(L)1 inhibitors revealed superior response and survival outcomes, and OS was closely correlated with disease control. No treatment-emergent adverse event led to permanent discontinuation of study treatment.
Conclusions:
Efti plus pembrolizumab was well-tolerated and revealed signs of antitumor activity in patients with NSCLC resistant to PD-(L)1 inhibitors, warranting further investigation. Trial registration number: NCT03625323.
2024-09-03·CLINICAL CANCER RESEARCH
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma
Article
作者: Patel, Grisma ; Pousa, Antonio L. ; Roxburgh, Patricia ; Bajaj, Pawan ; Brignone, Chrystelle ; Mueller, Christian ; Krebs, Matthew ; Doger, Bernard ; Forster, Martin ; Triebel, Frederic ; Peguero, Julio ; Brana, Irene ; Carcereny, Enric
Abstract:
Purpose::
Eftilagimod alpha (efti), a soluble LAG3 protein, activates antigen-presenting cells (APC) and downstream T cells. TACTI-002 (part C) evaluated whether combining efti with pembrolizumab led to strong antitumor responses in patients with second-line recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) while demonstrating good tolerability.
Patients and Methods::
In this multinational phase II trial using Simon’s two-stage design, patients who were PD-L(1)-naïve with R/M HNSCC who had failed first-line platinum-based therapy, unselected for PD-L1, received intravenous pembrolizumab (200 mg, once every 2 weeks) combined with subcutaneous efti (30 mg once every 2 weeks for 24 weeks and once every 3 weeks thereafter). The primary endpoint was objective response rate per RECIST 1.1 modified for immune-based therapy by investigator assessment. Additional endpoints included duration of response, progression-free survival, overall survival, and tolerability. Pharmacodynamic effects (absolute lymphocyte count) and Th1 cytokine biomarkers (IFNγ/CXCL10)] were evaluated in liquid biopsies.
Results::
Between March 2019 and January 2021, 39 patients were enrolled; 37 were evaluated for response. All patients received prior chemotherapy, and 40.5% were pretreated with cetuximab; 53.1% of patients had PD-L1 combined positive score <20. With a median follow-up of 38.8 months, the objective response rate was 29.7%, including 13.5% complete responders. The median duration of response was not reached. Rapid and sustained absolute lymphocyte count increase was observed in patients who had an objective response. Th1 biomarkers increased sustainably after first treatment. No unexpected safety signals were observed.
Conclusions::
Efti plus pembrolizumab was safe and showed encouraging antitumor activity and pharmacodynamic effects in patients with second-line head and neck squamous cell carcinoma (HNSCC), thus supporting further evaluation of this combination in earlier treatment lines.
2024-02-01·Clinical cancer research : an official journal of the American Association for Cancer Research
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Article
作者: Perjesi, Luca ; Dalenc, Florence ; Pápai, Zsuzsanna ; Duhoux, Francois P. ; Armstrong, Anne ; Brignone, Chrystelle ; Marme, Frederik ; Kuemmel, Sherko ; Jager, Agnes ; Dirix, Luc ; Cuypere, Eveline ; Triebel, Frederic ; Wildiers, Hans ; Schröder, Carolina P. ; Mueller, Christian ; Vuylsteke, Peter ; Menke-van der Houven van Oordt, Catharina Willemien ; Chan, Steve ; Huober, Jens ; Brain, Etienne
Abstract:
Purpose::
Eftilagimod alpha (efti), a soluble lymphocyte activation gene (LAG-3) protein and MHC class II agonist, enhances innate and adaptive immunity. Active Immunotherapy PAClitaxel (AIPAC) evaluated safety and efficacy of efti plus paclitaxel in patients with predominantly endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer (ET-resistant HR+ HER2− MBC).
Patients and Methods::
Women with HR+ HER2– MBC were randomized 1:1 to weekly intravenous paclitaxel (80 mg/m2) and subcutaneous efti (30 mg) or placebo every 2 weeks for six 4-week cycles, then monthly subcutaneous efti (30 mg) or placebo maintenance. Primary endpoint was progression-free survival (PFS) by blinded independent central review. Secondary endpoints included overall survival (OS), safety/tolerability, pharmacokinetics/pharmacodynamics, and quality of life. Exploratory endpoints included cellular biomarkers.
Results::
114 patients received efti and 112 patients received placebo. Median age was 60 years (91.6% visceral disease, 84.1% ET-resistant, 44.2% with previous CDK4/6 inhibitor treatment). Median PFS at 7.3 months was similar for efti and placebo. Median OS was not significantly improved for efti (20.4 vs. 17.5 months; HR, 0.88; P = 0.197) but became significant for predefined exploratory subgroups. EORTC QLQC30-B23 global health status was sustained for efti but deteriorated for placebo. Efti increased absolute lymphocyte, monocyte and secondary target cell (CD4, CD8) counts, plasma IFNγ and CXCL10 levels.
Conclusions::
Although the primary endpoint, PFS, was not met, AIPAC confirmed expected pharmacodynamic effects and demonstrated excellent safety profile for efti. OS was not significantly improved globally (2.9-month difference), but was significantly improved in exploratory biomarker subgroups, warranting further studies to clarify efti's role in patients with ET-resistant HER2− MBC.
173
项与 重组人源淋巴细胞激活基因-3（hLAG-3）融合蛋白(Immutep) 相关的新闻（医药）2024-12-16
Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti-LAG-3 small molecule programData also supports eftilagimod alfa’s (efti) preferential binding to a subset of MHC Class II molecules on antigen-presenting cells leading to their activation SYDNEY, AUSTRALIA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II (HLA-II) in humans. The publication is the first to show the crystal structure of a human LAG-3/HLA-II complex and provides a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti-LAG-3 small molecule program. Under the oversight of Professor Jamie Rossjohn FAA FRS, at Monash University’s Biomedicine Discovery Institute (BDI), and in collaboration with Immutep, this breakthrough is an exemplar of the importance of industry-academia alliances. The LAG-3 immune control mechanism is the exclusive focus of Immutep across both cancer and autoimmunity and a clinically validated target of deep interest throughout the academic, medical, and industry sectors. Dr. Jan Petersen, first author of the study, said: “The way the PD-1 and CTLA-4 immune checkpoint molecules bind to their respective ligands has been resolved for many years. However, the resolution of the interface between another important checkpoint molecule, LAG-3, and its main ligands, HLA-II molecules, has remained elusive. Solved using data collected at the Australian Synchrotron, a structure of a LAG-3/HLA-II complex provides a structural foundation to harness rationally for future development of antibodies and small molecule therapeutics designed to block LAG-3 activity.” Dr. Frédéric Triebel, Immutep’s CSO, added: “It is thrilling to be able to see and analyze the interactions taking place at the interface between the soluble homodimeric LAG-3 protein and its main ligand. We now better understand how efti uniquely acts as an MHC-II agonist by preferentially binding to a subset of MHC-II molecules clustered in lipid raft microdomains on the surface of antigen-presenting cells. These findings add to the strong foundation of our work with Professor Rossjohn and his team to develop a deeper understanding of the structure and function of the LAG-3 immune control mechanism, particularly as it relates to our anti-LAG-3 small molecule program.” The Crystal Structure of the Human LAG-3–HLA-DR1–Peptide Complex publication details how LAG-3 engages two HLA-II molecules (see Figure 1). The data in the publication supports efti’s (soluble LAG-3) preferential binding to a subset of MHC-II molecules on antigen-presenting cells leading to their activation. Figure 1: Human LAG-3 homodimer (with domains D1, D2, D3 and D4) binding to two separate HLA-II (MHC-II) molecules on the surface of an antigen-presenting cell (APC), imposing a distinct 38° offset angle. This figure has been modified from the original Figure 1c of Petersen et al to aid visualisation. About the Monash Biomedicine Discovery InstituteCommitted to making the discoveries that will relieve the future burden of disease, the Monash Biomedicine Discovery Institute (BDI) at Monash University brings together more than 120 internationally-renowned research teams. Spanning seven discovery programs across Cancer, Cardiovascular Disease, Development and Stem Cells, Infection, Immunity, Metabolism, Diabetes and Obesity, and Neuroscience, Monash BDI is one of the largest biomedical research institutes in Australia. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery. About ImmutepImmutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com. Australian Investors/Media:Catherine Strong, Sodali & Co+61 (0)406 759 268; catherine.strong@sodali.com U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; chris.basta@immutep.com ABN: 90 009 237 889
免疫疗法AACR会议
2024-12-12
Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1Positively, median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controlsComplete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectivelyTreatment continues to be well tolerated SYDNEY, AUSTRALIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb trial. This study evaluates eftilagimod alpha (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first line recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients with negative PD-L1 expression. The new promising data presented by Martin Forster, M.D., Ph.D., at the ESMO Immuno-Oncology (IO) Annual Congress 2024 includes strong overall survival, progression-free survival, and durability. This adds to the high response rates and favourable safety data previously reported on 12 July 2024. Prof. Martin Forster of the UCL Cancer Institute and University College London Hospital NHS Foundation Trust, London, UK, and TACTI-003 Investigator, stated, “The new survival and durability data, coupled with increasing complete responses, build on the strong response rates already established with this novel IO combination in head and neck squamous cell cancers with PD-L1 CPS <1. This difficult-to-treat disease places a high burden on patients who unfortunately have very limited treatment options that all include chemotherapy. Collectively, these impressive results build on the potential promise of efti to improve patient outcomes and expand populations that respond to anti-PD-1.” Results Data as of the 31 October 2024 cut-off date in evaluable 1L HNSCC patients (N=31) whose tumours express PD-L1 below 1 (Combined Positive Score [CPS] <1) and who typically do not respond well to anti-PD-1 therapy alone shows: Positively, median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%Promising progression-free survival (PFS) of 5.8 monthsStrong durability with interim median duration of response (DOR) of 9.3 monthsHigh 35.5% objective response rate (ORR) and 58.1% disease control rate (DCR), as reported on 12 JulyComplete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and iRECIST, respectively1Efti in combination with pembrolizumab continues to be well-tolerated with no new safety signals This data compares favourably to historical results from anti-PD-1 therapy alone in 1L HNSCC patients with PD-L1 CPS <1 including a 7.9-month median OS, 12-month OS rate of 39%, 2.1-month median PFS, 2.6-month median DOR, 5.4% ORR and 32.4% DCR with no complete responses2-3. Marc Voigt, CEO of Immutep, noted, “Despite the significant progress of cancer immunotherapy over the past decade and the positive change in the therapeutic landscape it has brought to bear, head and neck cancer patients with PD-L1 expression of less than one continue to have limited treatment options that all include chemotherapy. We believe this data is an encouraging step in the right direction towards potentially bringing a new approach to this underserved population, representing up to 20% of patients with this difficult disease.” Next StepsPatients with PD-L1 CPS <1 is an underserved patient population with limited treatment options. Immutep will continue to follow the maturing data from TACTI-003 and engage with regulatory authorities regarding potential paths forward. The ESMO IO poster is available on the Posters & Publications section of Immutep’s website. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. About ImmutepImmutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com. Complete response rate was 9.6%, according to RECIST 1.1 and iRECIST, respectively, at earlier cut-off date as previously reported on 12 July 2024Burtness, B. et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. Journal of Clinical Oncology 2022 40:21, 2321-2332. Note, the 5.4% ORR and 32.4% DCR are calculated from the 37 evaluable patients with CPS <1.Burtness B. et al. Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis. Cancer Res 15 August 2020; 80 (16_Supplement): LB–258. https://doi-org.libproxy1.nus.edu.sg/10.1158/1538-7445.AM2020-LB-258 Australian Investors/Media:Catherine Strong, Sodali & Co+61 (0)406 759 268; catherine.strong@sodali.com U.S. Media:Chris Basta, VP, Investor Relations and Corporate Communications+1 (631) 318 4000; chris.basta@immutep.com
免疫疗法临床2期临床结果
2024-12-11
Umabs DB作为目前全球最全面的抗体药物专业数据库，收录全球近10000个从临床前到商业化阶段抗体药物，涉及靶点1600+，涉及疾病种类2400+，研发机构2900+，覆盖药物蛋白序列、专利和临床等多种专业信息。Umabs DB药物数据库已正式开放上线，可访问www.umabs.com注册享受7天免费试用。
近期，根据UmabsDB数据库的记录，专注于LAG-3疗法开发的Immutep在clinical trials网站上，登记了一项LAG-3融合蛋白eftilagimod alpha（efti），联合PD-1抗体Pembrolizumab和化疗，在一线非细胞细胞肺癌患者中启动一项3期头对头临床试验TACTI-004（NCT06726265），该临床将于2025年3月启动，计划入组人数为756例。
TACTI-004的临床试验与默沙东联合进行开发，756例患者的入组不区分于PD-L1的表达，PFS和OS将作为双临床终点。
此前完成的早期临床INSIGHT-003的结果显示，相较于Pembrolizumab的历史数据KEYNOTE-189，联合疗法的响应率均高于K药，同时响应率随着PD-L1提高而显著提升，全人群的PFS达到12.7个月，OS达到32.9个月，比K药分别提高了3.7个月和10.9个月，三期临床值得期待。
Immutep专注于LAG-3疗法开发，此前在一线头颈癌方面，eftilagimod alpha+K药组的ORR高于30%，这是目前报道的最好的低PD-L1（<1%）治疗数据，特别是达到10%左右的CR，并且这些响应独立于HPV的状态，DCR达到60%左右（Immutep涨15%，LAG-3低PD-L1头颈癌数据被认可）。
同时Efti还在近10个癌种疗法中正在进行开发，一线头颈鳞状细胞癌也会基于目前顶线数据和监管机构沟通，进行进一步开发。
根据UmabsDB数据库的记录，目前全球仅只有一款LAG-3抗体疗法获批。BMS的PD-1抗体Nivolumab+LAG-3抗体Relatlimab固定剂量组合此前已经获批黑色素的治疗，将12个月的无进展生存期提高了一倍以上，同时目前也在多个实体瘤中进行三期研究。
2024年8月，根据UmabsDB数据库的记录，BMS在clinical trials网站上，登记其一项PD-1抗体Nivolumab+LAG-3抗体Relatlimab， 在PD-L1表达量为1-49%的非鳞状晚期非小细胞肺癌的一线治疗中，启动一项与默沙东PD-1抗体Pembrolizumab联合化疗的，头对头比对三期临床试验NCT06561386。
该临床预计将于2024年9月启动，计划入组人数为800例，直接挑战K+化疗在非小细胞肺癌的一线治疗中的统治地位（挑战王炸：BMS启动PD-1+LAG-3在一线非小细胞肺癌中与K药+化疗的头对头三期临床）。
此外，康方还启动了PD-1/LAG-3双抗药物AK129，联合CD47抗体，在PD-1/L1疗法耐药后的经典霍奇金淋巴瘤患者中，启动1/2期临床试验NCT06642792，该临床于2024年10月启动，计划入组人数为280例（280例：康方启动PD-1/LAG-3双抗+CD47联合疗法在霍奇金淋巴瘤临床）。
显然随着肿瘤免疫的疗法的不断深入，联用或双抗等多种疗法在不断威胁K药在肿瘤领域的基石地位，因此默沙东也在不断加强其护城河，一方面快速跟进引进PD-1/VEGF双抗（MSD：收购PD-1/VEGF双抗后的回应），另一方面也和Immutep等合作开展多种形式的联合疗法临床试验。
期待TACTI-004临床早日传来临床捷报，更多有关LAG3抗体的研发格局、具体信息、专利及临床等动态进展，敬请访问Umabs DB全球数据库（www.umabs.com）查阅。
拓展阅读：
Macrogenics启动下一代ADAM9 ADC临床
100% CR：默沙东更新ROR1 ADC二期淋巴瘤临床数据，即将启动三期临床
MSD：收购PD-1/VEGF双抗后的回应
HIV：中裕新药将ADC拓展至抗病毒领域
全球首个：默沙东ROR1 ADC启动三期临床试验
HER3终成药：HER2/HER3双抗Zenocutuzumab获FDA批准上市
百利天恒两款ADC在美启动临床
3000万美元首付：GSK引进映恩一款临床前ADC药物
“四字编码”时代下的信达全梳理
BioNtech启动PD-L1/VEGF双抗肺癌两项头对头三期临床
大涨68%：Janux的PSMA/CD3双抗再次取得突破疗效
316例：诺华启动BAFF-R抗体在狼疮性肾炎的三期临床
250例：默克CEACAM5 ADC开展泛癌种临床试验
AK112 vs PM8002：PD-1/VEGF第三次交锋
康方生物两款PD-1双抗均进入2024年医保目录
234例：安领科启动EGFR/c-Met双抗ADC临床
科伦博泰：本土首款Trop2 ADC获批上市
罗氏TIGIT抗体一线肺癌再次失败
876例：恒瑞启动c-met ADC单药及多种药物联用临床
科伦博泰首个双抗ADC启动临床
阿斯利康：ADC药物的临床剂量转化策略
最惨18A：北海康成市值仅为7520万港元，累计跌幅达到98.55%
2~3分钟完成给药：K药皮下制剂三期临床取得成功
ORR仅为5%：Immatics公布PRAME/CD3 TCR双抗临床数据
石药启动EGFR ADC+ATM抑制剂联合治疗临床
康方启动CD73/LAG3双抗临床试验
宫颈癌：迈威Nectin-4 ADC启动第3项三期临床
大涨53%：中国资产再次拯救美股biotech
翰森HS-20124为ROR-1 ADC药物？
翰森公开SEZ6 ADC专利
翰森公开CDH17 ADC专利
复宏汉霖公布两款ADC药物专利
BioNtech: 2024研发日
默沙东终于信了：5.88亿美元首付款引进礼新PD-1/VEGF双抗
映恩公开PD-L1/B7H3双抗ADC临床前数据
Hexagon：新型ADC毒素
提高渗透性：antikor开发高DAR值片段抗体ADC
Genmab终止两款CD3双抗开发，重聚焦后期管线
第一三共开发皮下HER2 ADC
三抗来袭：Aditum Bio以3500万美元首付款引进维立志博CD3/CD19/BCMA
强生公布膜依赖性MSLN/CD3双抗
金赛公开自主开发TOPOi ADC平台
礼来公布PTK7 ADC药物临床前数据
双payload ADC逐步工业化，多款药物即将进入临床
恒瑞SHR-A2009：国内首个HER3 ADC进入三期
ADC：抗原高表达的必要性？
关于Umabs DB
Umabs DB是目前全球最全面的抗体药物专业数据库，收录全球近10000个从临床前到商业化阶段抗体药物，涉及靶点1600+，涉及疾病种类2400+，研发机构2900+，覆盖药物蛋白序列、专利和临床等多种专业信息。Umabs DB药物数据库已正式开放上线，可访问www.umabs.com注册享受7天免费试用，更多信息可联系info@umabs.com
临床3期临床2期临床失败临床结果
100 项与 重组人源淋巴细胞激活基因-3（hLAG-3）融合蛋白(Immutep) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 重组人源淋巴细胞激活基因-3（hLAG-3）融合蛋白(Immutep) | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 转移性非小细胞肺癌 | 临床3期 | - | 2025-03-01 | |
| 转移性乳腺癌 | 临床3期 | 美国 | 2023-05-22 | |
| 转移性乳腺癌 | 临床3期 | 比利时 | 2023-05-22 | |
| 转移性乳腺癌 | 临床3期 | 格鲁吉亚 | 2023-05-22 | |
| 转移性乳腺癌 | 临床3期 | 摩尔多瓦 | 2023-05-22 | |
| 转移性乳腺癌 | 临床3期 | 西班牙 | 2023-05-22 | |
| 转移性HER2阴性乳腺癌 | 临床3期 | 美国 | 2023-05-22 | |
| 转移性HER2阴性乳腺癌 | 临床3期 | 比利时 | 2023-05-22 | |
| 转移性HER2阴性乳腺癌 | 临床3期 | 格鲁吉亚 | 2023-05-22 | |
| 转移性HER2阴性乳腺癌 | 临床3期 | 摩尔多瓦 | 2023-05-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 187 | eftilagimod alpha+pembrolizumab (KEYTRUDA®) (1st Line NSCLC) | 憲遞願範網網壓齋窪簾(艱餘觸構構簾鑰憲廠築) = 構鹽簾鹹獵製鹹憲膚齋 壓艱壓夢獵齋齋憲蓋鹽 (醖窪糧簾壓鑰簾夢鏇餘, 鏇鏇觸顧遞夢齋艱艱獵 ~ 廠壓廠構範構齋淵築築) 更多 | - | 2024-12-18 | ||
eftilagimod alpha+pembrolizumab (KEYTRUDA®) (2nd Line NSCLC) | 憲遞願範網網壓齋窪簾(艱餘觸構構簾鑰憲廠築) = 襯遞製網艱築艱遞齋醖 壓艱壓夢獵齋齋憲蓋鹽 (醖窪糧簾壓鑰簾夢鏇餘, 壓簾築襯夢齋範構窪顧 ~ 繭簾繭鏇夢蓋衊襯壓觸) 更多 | ||||||
临床2期 | 31 | (RECIST 1.1 + Cohort B) | 艱範憲醖網範範艱糧顧(醖顧憲獵鹹構遞顧憲顧) = 艱醖餘觸艱鑰蓋憲醖膚 糧糧鏇膚簾醖顧壓膚觸 (夢獵願艱繭夢繭窪願憲, 19.2 ~ 54.6) 更多 | 积极 | 2024-12-16 | ||
(iRECIST + Cohort B) | 艱範憲醖網範範艱糧顧(醖顧憲獵鹹構遞顧憲顧) = 憲觸鑰鹹衊艱製蓋網壓 糧糧鏇膚簾醖顧壓膚觸 (夢獵願艱繭夢繭窪願憲, 21.8 ~ 57.8) 更多 | ||||||
临床2期 | 一线 PD-L1 negative | 33 | Eftilagimod alpha (E) 30 mg | 憲觸願願夢窪壓蓋壓壓(憲窪顧範糧鑰築簾繭壓) = 築積鏇鑰顧鹽構醖選觸 積築鹹衊築膚繭壓鹽網 (願憲襯觸膚鬱壓醖製網 ) 更多 | 积极 | 2024-12-12 | |
Pembrolizumab (P) 400 mg | 憲觸願願夢窪壓蓋壓壓(憲窪顧範糧鑰築簾繭壓) = 鬱鏇膚蓋鏇製獵鹹遞鑰 積築鹹衊築膚繭壓鹽網 (願憲襯觸膚鬱壓醖製網 ) 更多 | ||||||
临床2期 | 36 | Eftilagimod alpha + Pembrolizumab | 網襯網顧築鏇醖廠鏇簾(壓夢糧簾觸窪鹹廠襯顧) = 憲膚艱獵衊築衊繭衊鬱 選餘鹽選鏇餘鏇鬱衊壓 (鹹顧簾積醖餘鏇窪糧齋 ) 更多 | 积极 | 2024-11-01 | ||
临床2期 | 118 | 範餘網糧網窪壓膚鏇積(廠積膚鏇鑰淵壓遞鏇繭) = 顧蓋齋獵衊窪壓餘繭獵 獵選繭網鬱艱廠衊醖鹹 (窪膚簾艱艱憲鹹鑰網膚 ) 更多 | 积极 | 2024-09-15 | |||
範餘網糧網窪壓膚鏇積(廠積膚鏇鑰淵壓遞鏇繭) = 廠選鹹鏇餘淵糧網積艱 獵選繭網鬱艱廠衊醖鹹 (窪膚簾艱艱憲鹹鑰網膚 ) 更多 | |||||||
临床2期 | 头颈部鳞状细胞癌 一线 | 138 | (PD-L1 Expression (CPS >20)) | 繭範鹽觸顧鬱膚顧繭鏇(鏇製鹹襯夢鏇憲醖鏇廠) = 觸醖鏇鏇齋獵繭顧餘襯 築糧觸鹹範衊鏇鬱繭膚 (淵積繭淵構願蓋衊糧蓋 ) 更多 | 积极 | 2024-06-27 | |
(PD-L1 Expression (CPS 1-19)) | 繭範鹽觸顧鬱膚顧繭鏇(鏇製鹹襯夢鏇憲醖鏇廠) = 鏇鏇膚積製艱膚衊齋糧 築糧觸鹹範衊鏇鬱繭膚 (淵積繭淵構願蓋衊糧蓋 ) | ||||||
临床2/3期 | 转移性乳腺癌 HER2 Negative | Hormone Receptor Positive | 6 | 製憲艱鹹淵艱餘夢製選(蓋膚願衊願壓醖膚壓繭) = none 積鏇鹹簾願顧範艱糧鏇 (網衊願積構願簾衊鑰齋 ) 更多 | 积极 | 2024-05-16 | ||
临床2期 | 软组织肉瘤 新辅助 | 6 | 艱窪選餘網鏇衊憲蓋願(觸蓋鬱餘膚淵憲醖製襯) = 願蓋繭積襯築獵簾繭選 鹹襯網構齋積鹹構憲襯 (繭獵繭鏇齋壓範艱鏇廠 ) | 积极 | 2024-05-02 | ||
临床2期 | 26 | 構蓋獵願壓製簾鬱範顧(壓獵築遞蓋襯餘積繭遞) = 淵齋顧艱餘艱醖繭簾網 蓋獵淵構膚淵鏇簾選積 (網鏇艱構繭構蓋顧鹽築 ) 更多 | 积极 | 2024-04-24 | |||
临床1期 | 非小细胞肺癌 一线 | 21 | Eftilagimod alpha + carboplatin + pemetrexed + pembrolizumab | 顧鬱夢簾鏇淵膚簾淵鑰(淵觸齋觸選選淵夢蓋淵) = 鹽築構膚遞鏇襯願繭鹽 築觸夢鏇鏇壓觸積鬱願 (顧襯壓遞窪艱糧憲膚蓋 ) 更多 | 积极 | 2023-10-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
标准版
¥16800
元/账号/年
新药情报库 ｜ 省钱又好用！
立即使用
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用